FIXX — Homology Medicines Share Price
- $53.92m
- -$28.73m
- $1.16m
- 11
- 21
- 38
- 12
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 0.74 | ||
Price to Tang. Book | 0.74 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 46.65 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -126.95% | ||
Return on Equity | -90.02% | ||
Operating Margin | -8015.74% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 1.67 | 2.7 | 33.97 | 3.21 | 1.16 | n/a | 2 | -26.32% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Homology Medicines, Inc. is a clinical-stage genetic medicines company. The Company is focused on transforming the lives of patients suffering from rare genetic diseases with unmet medical needs by addressing the underlying cause of the disease. Its platform is designed to utilize its human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs), to deliver single administration genetic medicines in vivo through a nuclease-free gene editing modality, gene therapy, or gene therapy to express antibodies platform (GTx-mAb), which is designed to produce antibodies throughout the body. The Company has gene editing and gene therapy clinical-stage programs in phenylketonuria (PKU) and Hunter syndrome (MPS II), a preclinical pipeline that includes a gene therapy candidate for metachromatic leukodystrophy and a GTx-mAb (vectorized antibody) candidate for paroxysmal nocturnal hemoglobinuria, as well as intellectual property on its family of 15 AAVHSCs.
Directors
- Kush Parmar NEC (40)
- Arthur Tzianabos PRE (58)
- W. Bradford Smith CFO (65)
- Albert Seymour CSO (53)
- Gabriel Cohn OTH (62)
- Steven Gillis IND (68)
- Richard Gregory IND (63)
- Matthew Patterson IND (49)
- Jeffrey Poulton IND (53)
- Alise Reicin IND (60)
- Mary Thistle IND (61)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 12th, 2015
- Public Since
- March 28th, 2018
- No. of Shareholders
- 14
- No. of Employees
- 7
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 58,133,540
- Address
- 1 Patriots Park, BEDFORD, 01730-2343
- Web
- https://www.homologymedicines.com/
- Phone
- +1 7813017277
- Auditors
- Deloitte & Touche LLP
Upcoming Events for FIXX
Q1 2024 Homology Medicines Inc Earnings Release
Homology Medicines Inc Annual Shareholders Meeting
Q2 2024 Homology Medicines Inc Earnings Release
Similar to FIXX
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 18:10 UTC, shares in Homology Medicines are trading at $0.93. This share price information is delayed by 15 minutes.
Shares in Homology Medicines last closed at $0.93 and the price had moved by +0.83% over the past 365 days. In terms of relative price strength the Homology Medicines share price has underperformed the S&P500 Index by -23.51% over the past year.
The overall consensus recommendation for Homology Medicines is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Homology Medicines does not currently pay a dividend.
Homology Medicines does not currently pay a dividend.
Homology Medicines does not currently pay a dividend.
To buy shares in Homology Medicines you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.93, shares in Homology Medicines had a market capitalisation of $53.92m.
Here are the trading details for Homology Medicines:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: FIXX
Based on an overall assessment of its quality, value and momentum Homology Medicines is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Homology Medicines is $1.50. That is 61.71% above the last closing price of $0.93.
Analysts covering Homology Medicines currently have a consensus Earnings Per Share (EPS) forecast of -$0.69 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Homology Medicines. Over the past six months, its share price has underperformed the S&P500 Index by -34.3%.
As of the last closing price of $0.93, shares in Homology Medicines were trading +1.8% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Homology Medicines PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.93.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Homology Medicines' management team is headed by:
- Kush Parmar - NEC
- Arthur Tzianabos - PRE
- W. Bradford Smith - CFO
- Albert Seymour - CSO
- Gabriel Cohn - OTH
- Steven Gillis - IND
- Richard Gregory - IND
- Matthew Patterson - IND
- Jeffrey Poulton - IND
- Alise Reicin - IND
- Mary Thistle - IND